TC
AVEO

TFS Capital’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

TFS Capital’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-11,162
Closed -$135K – 1001
2015
Q3 		$135K Sell
11,162
-5,766
-34% -$83.3K 0.01% 780
2015
Q2 		$295K Buy
16,928
+12,510
+283% +$225K 0.03% 664
2015
Q1 		$64K Buy
+4,418
New +$48.3K 0.01% 915
2014
Q4 		– Sell
-19,857
Closed -$220K – 1243
2014
Q3 		$220K Sell
19,857
-1,180
-6% -$15K 0.02% 844
2014
Q2 		$385K Buy
21,037
+3,374
+19% +$43.9K 0.03% 741
2014
Q1 		$264K Sell
17,663
-10,511
-37% -$189K 0.02% 1081
2013
Q4 		$516K Sell
28,174
-55,202
-66% -$1.11M 0.02% 815
2013
Q3 		$1.72M Buy
83,376
+50,185
+151% +$1.15M 0.08% 376
2013
Q2 		$830K Buy
+33,191
New +$1.42M 0.03% 684

Other funds holding AVEO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DVC
Deer VI & Co Larchmont, New York $2.23M AUM 9.32% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TFS Capital's AVEO Position: Q4 2015 in Review

TFS Capital sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q4 2015, closing a stake of 11,162 shares — an estimated $135K sold.

TFS Capital first reported a position in AVEO in Q2 2013 and held it in 9 quarters. The position peaked at $1.72M in Q3 2013. 44 funds tracked by Wall St. Rank hold AVEO as of Q4 2015.

  • TFS Capital reported no remaining AVEO Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
  • TFS Capital sold 11,162 AVEO Pharmaceuticals, Inc. shares in Q4 2015, an estimated $135K.
  • TFS Capital first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2013 and held it in 9 quarters.
  • TFS Capital's AVEO Pharmaceuticals, Inc. position peaked at $1.72M in Q3 2013.
  • 44 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q4 2015.

Based on TFS Capital's 13F filing for Q4 2015, filed 29 Jan 2016.